Abstract 26P
Background
Subcutaneous (SC) trastuzumab offers a distinctive approach to treat HER2-positive breast cancer in contrast with conventional intravenous (IV) infusion. SC can be administered at day care unit, which is potentially a big step forward with a more efficient treatment mode compared to IV administration at inpatient wards. This study aimed to quantify the impact of treatment mode transition by measuring its benefits to hospitals as well as patients in China.
Methods
This time-motion study was conducted in Tianjin Medical University Cancer Institute & Hospital, where breast cancer treatment mode was shifted from IV administration at inpatient ward to SC administration at day care unit. The duration of each specific task conducted by HCPs and the time patient spent were recorded by observers. Costs, including HCP salaries, medical consumables, and other relevant items, were collected from public sources. The study outcomes included hospital capacity improvements, time savings for HCPs, and cost reductions for hospital. Meanwhile, patients' time savings and cost of lost labor were also measured.
Results
The treatment mode transition significantly improved the hospital operation efficiency. For 80 patients visited per day, IV administration required 80 inpatient beds, but SC administration in day care unit only occupied 6 injection chairs, equals to a freeing up of around 24,960 bed-days annually for a hospital. Considering this optimized and reallocated inpatient resources, estimated potential benefits were CNY 68,902 per day and CNY 21,497,490 per year. In addition, the adoption of SC administration reduced nursing working hour by 81%. For patients and caregivers, the treatment time per cycle was 91% less than IV administrations, leading to total savings of CNY 19,681 per patient in terms of direct cost and productivity cost over a full course of treatment.
Conclusions
Besides saving time for HCPs and patients, trastuzumab SC can help optimize treatment process, improve overall quality and efficiency of healthcare system & hospital management, aligned with China policies of high-quality hospital development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract